Noxopharm Ltd (ASX: NOX) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Noxopharm Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $171.52 million
P/E Ratio 32.89
Dividend Yield N/A
Shares Outstanding 288.28 million
Earnings per share 0.016
Dividend per share N/A
Year To Date Return 15.31%
Earnings Yield 3.04%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Noxopharm Ltd (ASX: NOX)
Latest News

NOX ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Noxopharm Ltd

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

NOX Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
24 Sep 2021 $0.57 $0.02 3.70% 736,212 $0.54 $0.59 $0.54
23 Sep 2021 $0.54 $0.02 3.85% 123,241 $0.52 $0.54 $0.52
22 Sep 2021 $0.52 $-0.01 -1.90% 128,463 $0.54 $0.54 $0.51
21 Sep 2021 $0.53 $0.02 3.92% 349,913 $0.51 $0.53 $0.49
20 Sep 2021 $0.51 $-0.01 -1.94% 318,320 $0.51 $0.53 $0.51
17 Sep 2021 $0.52 $0.00 0.00% 295,165 $0.52 $0.52 $0.50
16 Sep 2021 $0.52 $0.02 4.00% 213,793 $0.52 $0.53 $0.51
15 Sep 2021 $0.50 $0.00 0.00% 107,776 $0.50 $0.50 $0.49
14 Sep 2021 $0.50 $0.00 0.00% 248,229 $0.50 $0.51 $0.49
13 Sep 2021 $0.50 $-0.02 -3.85% 756,027 $0.51 $0.52 $0.50
10 Sep 2021 $0.52 $0.01 1.96% 244,093 $0.52 $0.53 $0.52
09 Sep 2021 $0.51 $-0.02 -3.77% 306,878 $0.54 $0.54 $0.51
08 Sep 2021 $0.53 $0.02 3.88% 424,375 $0.51 $0.55 $0.51
07 Sep 2021 $0.52 $0.01 1.98% 291,794 $0.51 $0.53 $0.51
06 Sep 2021 $0.51 $-0.01 -1.94% 269,982 $0.52 $0.53 $0.51
03 Sep 2021 $0.52 $-0.01 -1.90% 636,087 $0.54 $0.54 $0.51
02 Sep 2021 $0.53 $-0.02 -3.70% 304,117 $0.54 $0.54 $0.52
01 Sep 2021 $0.54 $-0.01 -1.83% 650,385 $0.54 $0.54 $0.50
31 Aug 2021 $0.55 $-0.01 -1.80% 155,822 $0.56 $0.56 $0.55
30 Aug 2021 $0.56 $-0.02 -3.48% 376,678 $0.58 $0.58 $0.55

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
31 May 2021 Frederick (Fred) Bart Issued 3 $1,580,137
Issue of securities.
31 May 2021 Boris Patkin Issued 250 $183,750
Director remuneration.
29 Apr 2021 Boris Patkin Cancelled 250 $150,000
Cancellation of securities.
26 Feb 2021 Peter Marks Exercise 200 $60,000
Exercise of options.
26 Feb 2021 Peter Marks Buy 200 $60,000
Exercise of options.
26 Feb 2021 Graham Kelly Exercise 8 $2,400,000
Exercise of options.
26 Feb 2021 Graham Kelly Buy 8 $2,400,000
Exercise of options.
26 Feb 2021 Graham Kelly Expiry 4 $2,791,375
Options expired.
23 Feb 2021 Graham Kelly Sell 8 $5,760,000
Off-market trade.
15 Dec 2020 Boris Patkin Issued 250 $115,000
Director remuneration.
15 Dec 2020 Frederick (Fred) Bart Issued 3 $1,380,000
Director remuneration.
27 Nov 2020 Peter Marks Expiry 500 $317,500
Options expired.
18 Nov 2020 Graham Kelly Issued 62 $43,125
Issue of securities.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Frederick (Fred) Bart Non-Executive DirectorNon-Executive Chairman May 2020
Mr Bart has been Chairman and Managing Director of numerous private and public companies since 1980, focusing in manufacturing, technology, property and marketable securities. Fred Bart is Chairman of ASX listed companies, Electro Optic Systems Holdings Limited and Audio Pixels Holdings Limited and is a director of Weebit Nano Limited. Mr Bart also is a director of Immunovative Therapies Limited, an Israeli company involved in in the manufacture of cancer vaccines for the treatment of most forms of cancer.
Mr Peter Ashley Marks Non-Executive DirectorNon-Executive Deputy Chairman Mar 2016
Mr Marks brings over 30 years' experience in corporate advisory, investment banking and director/advisory roles to the Board. With several leading firms, Peter's corporate skills lie in capital raising for pre-IPO and listed companies, cross border M&A transactions, corporate underwriting, and venture capital transactions for companies in Australia, US & Israel. He provides strategic and corporate advice at various stages of technology commercialisation for companies to transition to an operating entity, and helps facilitate significant commercial transactions to create shareholder value. He is holding directorship with Alterity Therapeutics Limited (ASX: ATH) - since 29 July 2005 and Fluence Corporation Limited (ASX: FLC) - since 12 May 2015.
Mr Boris Patkin Non-Executive Director Mar 2020
Mr Patkin has experience in global capital markets through 30 years of experience in financial advisory work, business consulting and stockbroking.
Dr Graham E Kelly Executive DirectorChief Executive OfficerManaging Director Oct 2015
Mr Kelly developed a theory that dietary isoflavones were metabolised within the body into novel chemicals that possessed important hormone-like functions, and as such made important contributions to human health. That theory provided the basis for Graham leaving academia and founding the company, Norvet Ltd, which listed on the ASX in 1994. That company subsequently changed its name to Novogen Ltd and listed in the US on NASDAQ (1998). Graham was variously CEO, Executive Chairman and an Executive Director of Novogen, 1994-2006. He also was Executive Chairman of Marshall Edwards Inc (MEI) which listed on London's AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma Inc. Graham resigned from his executive and Board positions at Novogen and MEI in 2006.
Mr David James Franks Company Secretary Jan 2017
-
David James Franks Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Milligene Pty Ltd (The Ge + Pr Kelly Fam Trust) 36,489,106 17.11%
Mrs Eleanore Goodridge 9,727,989 4.56%
Rgt Capital Fund No 5 (Noxo) Pty Ltd 6,500,333 3.05%
Link Traders (Aust) Pty Ltd 4,941,224 2.32%
HSBC Custody Nominees (Australia) Limited 3,746,098 1.76%
Rhlc Pty Limited Rhlc S/F A/C 3,220,000 1.51%
Halcyon Nominees Pty Ltd Halcyon Super Fund A/C 3,001,003 1.41%
Jamber Investments Pty Ltd The Amber Schwarz Fam A/C 2,752,762 1.29%
Blackcourt (Nsw) Pty Limited Lawsam Super Fund A/C 2,596,276 1.22%
Mr Frederick Bart 2,538,462 1.19%
Drh Superannuation Pty Ltd Drh Superfund No 2 A/C 2,400,000 1.13%
Kale Capital Corporation Limited 2,280,506 1.07%
Suburban Holdings Pty Ltd The Suburban Super Fund A/C 2,015,565 0.95%
Link Traders (Aust) Pty Ltd I 1,790,776 0.84%
Helium Management Pty Ltd Helium S/F A/C 1,766,246 0.83%
UBS Nominees Pty Ltd 1,671,000 0.78%
Mr Lizhong Yu 1,638,000 0.77%
Lawsam Pty Ltd 1,542,424 0.72%
Berne No 132 Nominees Pty Ltd 331898 A/C 1,468,784 0.69%
Grandor Pty Ltd Mark Scott Family P/F A/C 1,400,000 0.66%

Profile

since

Note